三生国健核心技术人员翁志兵辞职，去年薪酬157万元高于董事长

Core Viewpoint - The resignation of key technical personnel, Weng Zhibing, from Sangfor Biopharma (SH688336) raises concerns about the company's leadership stability and potential impact on ongoing projects [1] Group 1: Resignation Details - Weng Zhibing submitted a written resignation due to personal reasons and will no longer hold any position within the company [1] - Weng has held various roles in the company since 2002, including positions related to cell culture and process development, and has been the general manager of the wholly-owned subsidiary Shanghai Shengguo Pharmaceutical Development Co., Ltd. since 2018 [1] Group 2: Compensation Information - In 2024, Weng Zhibing received a pre-tax compensation of 1.5746 million yuan, which is higher than the chairman's compensation of 995,100 yuan [2] Group 3: Company Performance - For the first three quarters of 2025, Sangfor Biopharma achieved operating revenue of 1.116 billion yuan, representing a year-on-year growth of 18.80%, and a net profit attributable to shareholders of 399 million yuan, reflecting a year-on-year increase of 71.15% [4] - As of the end of 2023, the company had 261 R&D personnel, which is projected to increase to 312 by the end of 2024 and 333 by mid-2025, accounting for 27.05%, 31.36%, and 32.55% of the total workforce, respectively [4] Group 4: Company Overview - Sangfor Biopharma, established in 2002, focuses on research in monoclonal antibodies, bispecific antibodies, and multifunctional recombinant proteins, with 13 innovative drugs at various stages of development [3]